RT Journal Article
SR Electronic
T1 Seminoma Patients Treated at a Minor Oncological Department During 1986-2010: Treatment and Outcome
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4253
OP 4260
VO 34
IS 8
A1 HEGE S. HAUGNES
A1 ØIVIND SOLHAUG
A1 JOHANNES STENBERG
A1 LINE V. HJELLE
A1 ROY M. BREMNES
YR 2014
UL http://ar.iiarjournals.org/content/34/8/4253.abstract
AB Aim: To present results for patients with seminoma treated at our University Clinic. Patients and Methods: All men treated for seminoma in 1986-2010 at the Department of Oncology, University Hospital of North Norway were included (n=232). Treatment was standardized from 2000 as the Swedish and Norwegian Testicular Cancer Project (SWENOTECA) published their first standardised seminoma treatment program (SWENOTECA V). Results: The percentage of patients administered adjuvant radiotherapy (RT) for clinical stage (CS) I decreased gradually from the late 1990s and was abandoned in 2005. Surveillance was the most common management strategy for CS I after 2000. Overall, disease in 1.9% and 11% of patients relapsed after adjuvant RT and surveillance, respectively. There were no relapses after treatment for metastatic disease. Cancer-specific survival was 100%, and overall survival 95% for the total group. Conclusion: The treatment outcome at our University Clinic is excellent with 100% cancer-specific survival, and is essentially a result of the bi-national SWENOTECA network.